{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T08:23:47Z","timestamp":1790411027581,"version":"4.1.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"22","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.vaccine.2017.04.086","type":"journal-article","created":{"date-parts":[[2017,5,13]],"date-time":"2017-05-13T00:00:41Z","timestamp":1494633641000},"page":"3169-3179","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Combined semi-empirical screening and design of experiments (DOE) approach to identify candidate formulations of a lyophilized live attenuated tetravalent viral vaccine candidate"],"prefix":"10.1016","volume":"36","author":[{"given":"Ashaben","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M.","family":"Erb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Strange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi S.","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozan S.","family":"Kumru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangeeta B.","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill A.","family":"Livengood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Volkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.04.086_b0005","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.addr.2014.10.002","article-title":"Live attenuated and inactivated viral vaccine formulation and nasal delivery: potential and challenges","volume":"93","author":"Tlaxca","year":"2015","journal-title":"Adv. Drug Delivery Rev"},{"key":"10.1016\/j.vaccine.2017.04.086_b0010","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1586\/erv.09.20","article-title":"Opportunities and challenges of developing thermostable vaccines","volume":"8","author":"Chen","year":"2009","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2017.04.086_b0015","doi-asserted-by":"crossref","first-page":"5507","DOI":"10.1016\/j.vaccine.2015.08.085","article-title":"Freeze-drying of live virus vaccines: a review","volume":"33","author":"Hansen","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.086_b0020","first-page":"1","article-title":"Formulation, stability, and delivery of live attenuated vaccines for human use","volume":"16","author":"Burke","year":"1999","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"10.1016\/j.vaccine.2017.04.086_b0025","first-page":"97","article-title":"Factors affecting the stability of viral vaccines","volume":"87","author":"Peetermans","year":"1996","journal-title":"Dev Biol Stand"},{"key":"10.1016\/j.vaccine.2017.04.086_b0030","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.biologicals.2014.05.007","article-title":"Vaccine instability in the cold chain: mechanisms analysis and formulation strategies","volume":"42","author":"Kumru","year":"2014","journal-title":"Biol: J Int Assoc Biol Stand"},{"key":"10.1016\/j.vaccine.2017.04.086_b0035","doi-asserted-by":"crossref","first-page":"3471","DOI":"10.1016\/j.vaccine.2015.05.071","article-title":"Evaluating the value proposition for improving vaccine thermostability to increase vaccine impact in low and middle-income countries","volume":"33","author":"Karp","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.086_b0040","doi-asserted-by":"crossref","first-page":"3592","DOI":"10.1128\/AEM.61.10.3592-3597.1995","article-title":"Trehalose and sucrose protect both membranes and proteins in intact bacteria during drying","volume":"61","author":"Leslie","year":"1995","journal-title":"Appl Environ Microbiol"},{"key":"10.1016\/j.vaccine.2017.04.086_b0045","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1023\/A:1016043114998","article-title":"Development of a stable freeze-dried formulation of recombinant human interleukin-1 receptor antagonist","volume":"13","author":"Chang","year":"1996","journal-title":"Pharm Res"},{"key":"10.1016\/j.vaccine.2017.04.086_b0050","doi-asserted-by":"crossref","first-page":"4301","DOI":"10.1016\/j.vaccine.2011.09.114","article-title":"Flaviviruses and flavivirus vaccines","volume":"30","author":"Heinz","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.086_b0055","doi-asserted-by":"crossref","first-page":"e0003655","DOI":"10.1371\/journal.pntd.0003655","article-title":"A critical assessment of vector control for dengue prevention","volume":"9","author":"Achee","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2017.04.086_b0060","doi-asserted-by":"crossref","first-page":"7456","DOI":"10.1016\/j.vaccine.2011.07.054","article-title":"Novel formulations enhance the thermal stability of live-attenuated flavivirus vaccines","volume":"29","author":"Wiggan","year":"2011","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2017.04.086_b0065","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1016\/j.vaccine.2015.05.010","article-title":"The dengue vaccine pipeline: implications for the future of dengue control","volume":"33","author":"Schwartz","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.086_b0070","doi-asserted-by":"crossref","first-page":"7112","DOI":"10.1016\/j.vaccine.2015.11.022","article-title":"Development of a recombinant, chimeric tetravalent dengue vaccine candidate","volume":"33","author":"Osorio","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.086_b0075","first-page":"219","article-title":"Stability of yellow fever vaccine","volume":"87","author":"Monath","year":"1996","journal-title":"Dev Biol Stand"},{"key":"10.1016\/j.vaccine.2017.04.086_b0080","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/jps.24211","article-title":"Characterization of an oncolytic herpes simplex virus drug candidate","volume":"104","author":"Kumru","year":"2015","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.vaccine.2017.04.086_b0085","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1002\/jps.22618","article-title":"Multidimensional methods for the formulation of biopharmaceuticals and vaccines","volume":"100","author":"Maddux","year":"2011","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.vaccine.2017.04.086_b0090","unstructured":"Q11-Development and manufacture of drug substances (chemical entities and biotechnological\/biological entities). International Conference in Harmonization (ICH). 2012."},{"key":"10.1016\/j.vaccine.2017.04.086_b0095","unstructured":"Q8(R2)-Pharmaceutical Development, International Conference in Harmonization (ICH). 2009."},{"key":"10.1016\/j.vaccine.2017.04.086_b0100","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1208\/s12249-010-9521-x","article-title":"Considerations in developing a target product profile for parenteral pharmaceutical products","volume":"11","author":"Lambert","year":"2010","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.vaccine.2017.04.086_b0105","unstructured":"Jeffrey T. Blue JRS, Akhilesh Bhambhani. Process Scale-Up and Optimization of Lyophilized Vaccine Products. Lyophilized Biologics and Vaccines. p. 179\u2013210."},{"key":"10.1016\/j.vaccine.2017.04.086_b0110","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.addr.2011.07.006","article-title":"Protein-excipient interactions: mechanisms and biophysical characterization applied to protein formulation development","volume":"63","author":"Kamerzell","year":"2011","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.vaccine.2017.04.086_b0115","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1177\/0049124104268644","article-title":"Multimodel inference: understanding AIC and BIC in model selection","volume":"33","author":"Burnham","year":"2004","journal-title":"Sociol Meth Res"},{"key":"10.1016\/j.vaccine.2017.04.086_b0120","series-title":"Development of vaccines: from discovery to clinical testing","article-title":"Effect of buffers and stabilizers on vaccine stability and efficacy","author":"Apte","year":"2011"},{"key":"10.1016\/j.vaccine.2017.04.086_b0125","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jviromet.2013.12.020","article-title":"Evaluation of the thermal stability of a novel strain of live-attenuated mumps vaccine (RS-12 strain) lyophilized in different stabilizers","volume":"199","author":"Jamil","year":"2014","journal-title":"J Virol Meth"},{"key":"10.1016\/j.vaccine.2017.04.086_b0130","doi-asserted-by":"crossref","first-page":"4728","DOI":"10.1016\/S0264-410X(03)00512-7","article-title":"Comparative efficacy of various chemical stabilizers on the thermostability of a live-attenuated peste des petits ruminants (PPR) vaccine","volume":"21","author":"Sarkar","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.086_b0135","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1002\/jps.20157","article-title":"Development of stable liquid formulations for adenovirus-based vaccines","volume":"93","author":"Evans","year":"2004","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.vaccine.2017.04.086_b0140","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1006\/biol.1998.0157","article-title":"Stability of 17D yellow fever virus vaccine using different stabilizers","volume":"26","author":"Adebayo","year":"1998","journal-title":"Biol: J Int Assoc Biol Stand"},{"key":"10.1016\/j.vaccine.2017.04.086_b0145","doi-asserted-by":"crossref","first-page":"6447","DOI":"10.1016\/j.vaccine.2007.06.054","article-title":"Rational design of an influenza subunit vaccine powder with sugar glass technology: preventing conformational changes of haemagglutinin during freezing and freeze-drying","volume":"25","author":"Amorij","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.086_b0150","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/s12250-011-3205-x","article-title":"Evaluation of efficacy of stabilizers on the thermostability of live attenuated thermo-adapted Peste des petits ruminants vaccines","volume":"26","author":"Riyesh","year":"2011","journal-title":"Virol Sin"},{"key":"10.1016\/j.vaccine.2017.04.086_b0155","unstructured":"Vaccines Licensed for Use in the United States. US Food and Drug Administration; 2014. http:\/\/www.fda.gov\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/ucm093833.htm"},{"key":"10.1016\/j.vaccine.2017.04.086_b0160","unstructured":"Immunization, Vaccines and Biologicals. World Health Organization; 2014. http:\/\/www.who.int\/immunization\/diseases\/en\/"},{"key":"10.1016\/j.vaccine.2017.04.086_b0165","unstructured":"Daniel C. Vellom JEW, Amy Woiszwillo, Dara O'Neil, Jennifer Woiszwillo, Cole Woiszwillo, et al. Stabilization of vaccines by lyophilization, US 2010\/0247573 A1 2010."},{"key":"10.1016\/j.vaccine.2017.04.086_b0170","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1007\/s11095-014-1359-6","article-title":"Development of thermostable lyophilized inactivated polio vaccine","volume":"31","author":"Kraan","year":"2014","journal-title":"Pharm Res"},{"key":"10.1016\/j.vaccine.2017.04.086_b0175","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/0042-6822(65)90332-6","article-title":"Different effects of MgC1-2 and MgSO-4 on the thermostability of viruses","volume":"26","author":"Wallis","year":"1965","journal-title":"Virology"},{"key":"10.1016\/j.vaccine.2017.04.086_b0180","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1006\/abbi.1999.1175","article-title":"Hydrogen bonding between sugar and protein is responsible for inhibition of dehydration-induced protein unfolding","volume":"365","author":"Allison","year":"1999","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.vaccine.2017.04.086_b0185","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S0167-4838(01)00163-7","article-title":"Activation of enzymes for nonaqueous biocatalysis by denaturing concentrations of urea","volume":"1546","author":"Guo","year":"2001","journal-title":"Biochimica et Biophysica Acta"},{"key":"10.1016\/j.vaccine.2017.04.086_b0190","unstructured":"Francon A, Brass O, Chouvenc P, Leleu A. Stabilizer and vaccine composition comprisingone or more live attenuated flaviviruses, WO 2010003670 A1, 2010."},{"key":"10.1016\/j.vaccine.2017.04.086_b0195","unstructured":"Liu Jingye, Wang P, Li Guangpu, Xie Baosheng, Song Zongming, Li Shuyan, et al. Freeze-dried hepatitis A attenuated live vaccine and its stabilizer, US 6884422 B1, 2005. 2005"},{"key":"10.1016\/j.vaccine.2017.04.086_b0200","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/jps.24655","article-title":"Addition of amino acids to further stabilize lyophilized sucrose-based protein formulations: i. screening of 15 amino acids in two model proteins","volume":"105","author":"Forney-Stevens","year":"2016","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.vaccine.2017.04.086_b0205","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/jps.10296","article-title":"Thermal stability of vaccines","volume":"92","author":"Brandau","year":"2003","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.vaccine.2017.04.086_b0210","series-title":"Excipients for Use in Lyophilized Pharmaceutical Peptide, Protein, and other Bioproducts","first-page":"139","author":"Costantino","year":"2004"},{"key":"10.1016\/j.vaccine.2017.04.086_b0215","first-page":"B2","article-title":"Vaccine formulations and uses thereof","volume":"8795683","author":"Oberreither","year":"2014","journal-title":"US"},{"key":"10.1016\/j.vaccine.2017.04.086_b0220","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1002\/jps.20104","article-title":"Influenza vaccine powder formulation development: spray-freeze-drying and stability evaluation","volume":"93","author":"Maa","year":"2004","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.vaccine.2017.04.086_b0225","unstructured":"Evans RK, Volkin DB. Adenovirus formulations, WO 2001066137 A1, 2001."},{"key":"10.1016\/j.vaccine.2017.04.086_b0230","unstructured":"Evans RK, Yin DH. Preservative-containing virus formulations, WO 2005052116 A2, 2005."},{"key":"10.1016\/j.vaccine.2017.04.086_b0235","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1037\/1082-989X.2.3.235","article-title":"Misleading interaction and curvilinear terms","volume":"2","author":"Ganzach","year":"1997","journal-title":"Psychol Meth"},{"key":"10.1016\/j.vaccine.2017.04.086_b0240","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1016\/j.vaccine.2015.03.017","article-title":"M-M-R((R))II manufactured using recombinant human albumin (rHA) and M-M-R((R))II manufactured using human serum albumin (HSA) exhibit similar safety and immunogenicity profiles when administered as a 2-dose regimen to healthy children","volume":"33","author":"Wiedmann","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.04.086_b0245","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12887-016-0546-5","article-title":"Varicella vaccine without human serum albumin versus licensed varicella vaccine in children during the second year of life: a randomized, double-blind, non-inferiority trial","volume":"16","author":"Prymula","year":"2016","journal-title":"BMC Pediatrics"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17306023?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17306023?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T13:59:39Z","timestamp":1602079179000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17306023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":49,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S0264410X17306023"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.04.086","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combined semi-empirical screening and design of experiments (DOE) approach to identify candidate formulations of a lyophilized live attenuated tetravalent viral vaccine candidate","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.04.086","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}